Across TCGA pan-cancer cohorts, SEPHS1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEPHS1 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SEPHS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEPHS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
OV, STAD, and UCEC are the cancer types where SEPHS1 Mutation most reproducibly stratifies survival.